Related by context. All words. (Click for frequent words.) 66 Final Approval 65 Regulatory Approvals 64 Fast Track Status 64 Expanded Indication 63 Submits Application 63 Patent Covering 63 Antitrust Clearance 63 Conditional Approval 63 Positive Opinion 63 Granted Orphan Drug 63 NDA Submission 63 Orphan Status 62 Orphan Drug Status 62 Receives Approval 62 FDA Clearance 61 FDA Approval 61 Receives Orphan Drug Designation 61 FDA Approvals 61 Phase III Clinical Trial 61 Psoriasis Drug 60 Obtains Approval 60 Submits NDA 60 Receives Conditional 60 Systemic Delivery 60 GRAS Status 60 Exclusive License 60 Receives Fast Track 59 k Clearance 59 SFDA Approval 59 Marketing Authorisation Application 59 Pivotal Phase III 59 Shareholder Approval 59 FDA Accepts 59 Submits Response 59 IND Application 59 Commence Phase 59 Files IND 59 Receives Clearance 59 Milestone Payment 59 Meets Primary Endpoint 59 Receives Orphan Drug 59 Receives Milestone Payment 59 Begin Clinical Trials 59 Receives Regulatory 59 Demonstrates Significant 59 Receives Marketing Authorization 59 Marketing Authorisation 59 Files Patent Application 59 Approvable 59 FDA Orphan Drug 59 Milestone Payment From 59 Regulatory Clearance 58 Patents Covering 58 Testosterone Gel 58 Seasonal Influenza Vaccine 58 Completes Patient Enrollment 58 Announces FDA Clearance 58 IND Filing 58 Miraculins Announces 58 Successfully Completed 58 Initiates Phase II 58 Tentative Approval 58 Drug Candidate 58 Lupus Drug 58 Phase III Trial 58 Generic Version 58 Gets Approval 58 Grants Orphan Drug 58 Orphan Designation 58 Receives Approval From 58 Prostate Cancer Vaccine 58 Successful Completion 58 Initiates Clinical 58 Receives Positive Opinion 58 Orphan Drug designation 58 Clinical Trial Evaluating 58 Initiate Clinical Trial 58 Confirms Efficacy 58 Closes Financing 58 Signs Option Agreement 57 Patient Enrolment 57 Milestone Payments 57 BioSante Pharmaceuticals Announces 57 Taro Receives 57 Initiates Enrollment 57 Announces Issuance 57 Patient Enrollment 57 Phase IIb Trial 57 FDA Clears 57 Pivotal Trial 57 Patents Issued 57 Commences Phase 57 Patients Treated 57 Fast Track designations 57 Receives Approvals 57 Receives FDA Clearance 57 Receives Approvable Letter 57 Exercises Option 57 Rheumatoid Arthritis Drug 57 Gets FDA Clearance 57 Mylan Receives Approval 57 Marketing Authorization 57 Key Milestones 57 Receives CE Marking 57 Patent Broadly Covering 57 Announces Tentative Approval 57 Enters Into Agreement 57 PDUFA Date 57 Study Evaluating 56 Reacquires 56 Inks MOU 56 Identifies Potential 56 VIVUS Announces 56 Expedited Review 56 Obtains Regulatory 56 Improves Survival 56 Patent Upheld 56 Investigational Device Exemption 56 Receives Shareholder Approval 56 Significantly Increases 56 Completes Enrollment 56 NYSE Amex Listing 56 Preliminary Approval 56 Pivotal Study 56 Supplemental Biologics License Application 56 Initiates Phase III 56 Interferon Alpha 56 Secures Financing 56 Seeks Approval 56 DOR BioPharma Announces 56 Announces Successful Completion 56 Preotact R 56 Obtains CE Mark 56 Initiates Clinical Trials 56 FDA Approvable Letter 56 Initiates Clinical Trial 56 Announces Initiation 56 Files Investigational 56 Receives Patent 56 CONBRIZA 56 Pivotal Clinical Trial 56 Reports Positive 56 Private Placement Closed 56 Completes Initial 56 Closes Sale 56 ProLogis Closes 56 regulatory approval 56 Executes Agreement 56 Submits Supplemental 56 Patent Issued 56 Bird Flu Vaccine 56 Japanese Encephalitis Vaccine 56 Receives Conditional Approval 55 Submits Biologics License Application 55 Provides Clarification 55 Approve Merger 55 Cholesterol Lowering Drug 55 liver resection surgeries 55 Commences Phase III 55 Drilling Permit 55 Receive Milestone Payment 55 Drug Approvals 55 Marketing Authorization Application 55 Pafuramidine 55 Single Dose 55 Teva Provides Update 55 Receives Notification 55 Announce Receipt 55 Provides Updates 55 Arthritis Drug 55 Receives Permit 55 Supply Agreements 55 Listing Approval 55 Hepatitis B Vaccine 55 Study Showed 55 Diamyd Medical Diamyd 55 Transdermal Patch 55 Schizophrenia Drug 55 Important Milestone 55 Study Demonstrates 55 Strengthens Balance Sheet 55 Epilepsy Drug 55 Advisers Urge 55 Terminates Agreement 55 Lorus Therapeutics Announces 55 Clinical Trial Results 55 Closes Oversubscribed 55 Product Designation 55 Monoclonal Antibody 55 Amends Agreement 55 Commercialize 55 Orphan Drug status 55 Million Milestone Payment 55 Commence Trading 55 Begins Dosing 55 Entry Into 55 Cervical Cancer Vaccine 55 Migraine Drug 55 Receives CE 55 Pending Acquisition 55 Biotech Firm 55 Completes Financing 55 Announces Cancellation 55 Drug Eluting Stent 55 Amend Merger Agreement 55 Enters Negotiations 55 Develop Novel 55 Patients Treated With 55 Lung Cancer Drug 55 Poniard Pharmaceuticals Announces 55 Signs Agreements 55 Lexiscan TM 55 Phase III Trials 55 Achieves Significant 54 Enrolls First 54 Trobalt 54 Adjuvant Treatment 54 Phase 2a Trial 54 Announcement acc 54 Intravenous Formulation 54 Inhaled Insulin 54 Generic Version Of 54 Successfully Completes Phase 54 Milestone Achieved 54 FDA Approves 54 Completes Dosing 54 Improved Survival 54 Orphan Drug Designation 54 ENLIGHT 54 Shows Promising 54 Announces Commencement 54 OMP designation 54 Sign Definitive Agreement 54 Completes Tender Offer 54 Expands Scope 54 WorldHeart Announces 54 Receives Positive 54 Presents Positive 54 Receives Favorable 54 CE Marked 54 Voluntarily Withdraw 54 Fast Track Designation 54 Resubmission 54 Nasdaq Notice Regarding 54 Initiate Phase III 54 Completes Transaction 54 Advanced Melanoma 54 Phase 1b Clinical Trial 54 Significantly Improves 54 Receives Authorization 54 Civacir 54 Submits Investigational 54 Wins Approval 54 Completes Private Placement 54 Signs LOI 54 Consummates 54 orphan designation 54 Investigational Compound 54 Recommends Approval 54 Enters Into Collaboration 54 HSR Waiting Period 54 Drug Fails 54 Present Preclinical Data 54 Phase IIb Clinical Trial 54 EUR# Million 54 GMP Certification 54 Be Studied 54 Terminates Contract 54 Sagent Pharmaceuticals Announces 54 Receives Tentative Approval 54 euro adhoc Intercell AG 54 Amends Terms 54 SYCREST 54 Dual Listing 54 BioElectronics Announces 54 Approves Merger 54 Reports Preclinical Data 54 Investigational Treatment 54 Phase III Clinical Trials 54 vinorelbine emulsion 54 Closes Private Placement 54 First Patient Enrolled 54 Acquire Controlling Interest 54 Data Suggest 54 FDA Warns 54 Obtains License 54 Prolongs Survival 54 Provides Update Regarding 54 Announce Commencement 54 Resubmits 54 Updates Status 54 Approval 54 Blood Pressure Drug 54 Fully Subscribed 54 Patient Treated 53 Efficacy Trial 53 PRN FDA Approves 53 Warrants Exercised 53 Swine Flu Vaccines 53 Signs MOU 53 FDA Okays 53 Combination Treatment 53 Demonstrates Positive 53 Private Placement Financing 53 CE Marking 53 Oral Interferon 53 Drill Permits 53 Phase 2b Clinical Trial 53 Partial Settlement 53 Completes Reverse Merger 53 NASDAQ Deficiency Notice 53 Underwritten Public 53 Reveals Positive 53 Announce Collaboration Agreement 53 Previously Announced Private Placement 53 Initiates Phase 2b 53 Rotavirus Vaccine 53 Drug Maker 53 CHMP Opinion 53 Restructures Debt 53 Misonix Announces 53 License Application 53 Jointly Develop 53 Study Confirms 53 Shareholders Approve Proposed 53 Sunesis Pharma 53 Announce License Agreement 53 Enters Into Joint Venture 53 Abstral ® 53 Renegotiates 53 Begins Shipment 53 Trial Evaluating 53 Obtains Exclusive License 53 Spectrum Pharmaceuticals Announces 53 Ebola Vaccine 53 First Patient Dosed 53 BioSante Pharmaceuticals Reports 53 Gout Drug 53 Completes Previously Announced 53 Crowflight Announces 53 Chemotherapy Regimen 53 Significant Increase 53 Settle Patent Litigation 53 BioDelivery Sciences Announces 53 Anticancer Drug 53 Generic Versions 53 Successfully Closes 53 ARIXTRA R 53 Achieves Milestone 53 Presents Positive Preclinical 53 TM Drug Eluting 53 Pandemic Influenza Vaccine 53 Acquire Remaining 53 Panel Backs 53 Long Term Efficacy 53 Immunomedics Announces 53 Licensing Pact 53 Oral Calcitonin 53 Increases Size 53 Adjunctive Therapy 53 Underwriters Exercise 53 Closes Second Tranche 53 Asset Swap 53 Milestone Reached 53 Significant Milestones 53 Increases Ownership 53 STERIS Corporation Announces 53 Announces Granting 53 Subsidiary Enters 53 #k Clearance 53 Chronic Hepatitis B 53 ACAPODENE R 53 NASDAQ Delisting Notice 53 Gets Clearance 53 Finalizes Acquisition 53 Submits IND 53 Receives Confirmation 53 Tostrex 53 Ephedra Ban 53 Cancer Vaccine 53 GTC recombinant human 53 Receives Unsolicited 53 Metformin HCl 53 Successfully Completes 53 Exercises Warrants 53 Pacific Rubiales Announces 53 Improve Survival 53 Bazedoxifene 53 Osteoporosis Drug 53 Regains Full 53 Medicure Announces 53 Announces Non Brokered 53 Antitrust Approval 53 Announces Termination 53 Acquire Remaining Shares 53 Moves Towards 53 Dupuytren Contracture 53 C1 Inhibitor 53 Combination Clinical Trial 53 Remain Listed 53 Oral Cladribine 53 Inflation Linked Bonds 53 Announces Consummation 53 Patent Infringement Litigation 53 Cellegesic 53 Cholesterol Drug 53 Binding Offer 53 LUCASSIN 53 Announce Completion 53 Expansion Into 53 Presents Preclinical Data 53 Files Shelf Registration Statement 53 Announces Licensing Agreement 53 Proxy Proposals 53 Closes Merger 53 Voluntarily Withdraws 53 Complete Merger 53 Acute Attacks 52 Substantially Increases 52 Blood Thinner 52 JAK Inhibitor 52 Integra LifeSciences Announces 52 Permit Approval 52 Demonstrates Statistically Significant 52 Commences Operations 52 Asthma Treatment 52 Extends Deadline 52 ISO Certification 52 Completes Second Tranche 52 Demonstrates Long Term 52 Alvesco ® 52 Smallpox Vaccine 52 Release Capsules 52 Shares Soar 52 Trading Halt 52 Demonstrates Ability 52 Tolerability Study 52 Patients Enrolled 52 ISO #:# Certification [001] 52 Finalizes Agreement 52 Announce Merger Agreement 52 Million Doses 52 Severe Sepsis 52 ANDA Filing 52 Closes Previously Announced 52 Avian Influenza Vaccine 52 Combination REOLYSIN R 52 Fuwei Films Announces 52 Survival Benefit 52 Sign Licensing Agreement 52 Sensipar R 52 Achieves Primary Endpoint 52 Reduces Debt 52 GATTEX TM 52 Regulators Approve 52 DTC Eligibility 52 CMDCAS 52 Metastatic Colorectal Cancer 52 Regulator Approves 52 Stereotaxis Announces 52 Disease Modifying 52 Randomized Study 52 Certej Project 52 Rheumatoid Arthritis Patients 52 Treat Diseases HTDS 52 Announces Filing 52 Argatroban 52 Collaborators Present 52 Scientists Develop 52 Zenpep 52 Glatiramer Acetate 52 Clinical Trial Data 52 Announces Underwriters Exercise 52 Gets Tentative 52 Announce Expiration 52 Shows Statistically Significant 52 Demonstrates Potential 52 Receives Permission 52 TriCo Bancshares Announces 52 Extends Offer 52 Listing Compliance 52 Advanced Colorectal Cancer 52 GTC recombinant form 52 Significant Milestone 52 Announces Receipt 52 Nasdaq Delisting Notice 52 Nanophase Announces 52 Phase 2b Trial 52 Vaccine Adjuvant 52 Carboplatin Paclitaxel 52 Drill Permit 52 Levoleucovorin 52 Subsidiary Signs 52 Desvenlafaxine Succinate 52 Initiate Phase II 52 Breast Cancer Recurrence 52 Toremifene 52 Subsidiary Acquires 52 Malaria Vaccine 52 Enters Option Agreement 52 Unsolicited Tender Offer 52 FY# Loss Widens 52 Lambert Eaton Myasthenic 52 EUR# Mln 52 Previously Announced 52 Clarifies Status 52 Announces Reverse Split 52 Completes Non Brokered 52 Bought Deal Financing 52 HCV Protease Inhibitor 52 Earns Milestone Payment 52 Further Validates 52 Strengthens Presence 52 RNAi Therapeutics 52 Expanding Presence 52 Proven Effective 52 Regulator Fines 52 Nicotine Vaccine 52 Interferon Gamma 52 Improves Outcomes 52 Extends Tender Offer 52 Board Unanimously Rejects 52 Enters Into Definitive Agreement 52 Significantly Improved 52 Confirmatory Phase 52 Drilling Permits 52 Stem Cell Treatment 52 Shingles Vaccine 52 Projected Release Date 52 Announces Postponement 52 PPD Declares 52 Pivotal Phase II 52 Liberte TM 52 MedPulser 52 Hat Trick Beverages HKBV 52 Completes Due Diligence 52 Debt Repayment 52 Pivotal Trials 52 Demonstrates Improved 52 Receives Tentative FDA 52 VISICOL R 52 Announces Private Placement 52 Campto 52 Mutual Recognition Procedure 52 OVIT 52 Updates Guidance 52 Million Private Placement 52 BRILINTA 52 Successfully Concludes 52 Clinical Study Shows 52 Complies With 52 Dantrium R 52 Subsidiary Completes 52 Patent Dispute 52 Enters Agreement 52 OLpur TM H2H 52 Submits Revised 52 Orphan Drug designations 52 Diabetic Ulcers 52 TB Vaccine 52 Lanthanum Carbonate 51 ™ Paclitaxel Eluting 51 Receives Commitment 51 Achieve Significant 51 Phase IIa Clinical Trial 51 Small Molecule 51 Updates Shareholders 51 Initiates Phase 51 First Tranche 51 Announces Debt Settlement 51 Signs Joint Venture 51 Closes Private Placements 51 Initiate Phase 51 Anemia Drug 51 prasterone 51 CIP TRAMADOL ER 51 Nasdaq Deficiency Notice 51 Grants Incentive 51 Over Allotment Option Exercised 51 Testosterone Patch 51 Announces Intent 51 H#N# Vaccines 51 Weight Loss Drug 51 First Patient Treated 51 Acquires Controlling Interest 51 Announces Positive 51 Tissue Repair 51 Successful Launch 51 Tumor Targeting 51 Fancamp Announces 51 Expand Capacity 51 Non Brokered Financing 51 Recurrent Breast Cancer 51 Licenses Novel 51 Contaminated Heparin 51 Drug Eluting Stent System 51 Acquire Majority 51 Comprehensive Overview 51 Endovascular Treatment 51 submitted supplemental Biologics 51 Becomes Effective 51 Initiates Dosing 51 Pneumococcal Vaccine 51 Announces Shareholder Approval 51 R lenalidomide 51 Diabetic Patients 51 Presents Preclinical 51 Entered Into 51 Faces Setback 51 Significantly Reduces 51 Enters Into Negotiations 51 Complicated Skin 51 Signs Binding Agreement 51 Combination Therapy 51 Generic Protonix 51 Positive Feasibility Study 51 Nivestim 51 Oral Insulin 51 Enters Into Definitive 51 Efficacy Results 51 Accelerated Approval 51 Tezampanel 51 Sestamibi 51 Subsidiary Wins 51 Cash Infusion 51 PROMUS TM 51 Gastric Cancer 51 Announce Successful Completion 51 Immunotherapeutic 51 Receives Complete Response 51 More Than Doubled 51 REG1 Anticoagulation System 51 Handok Pharmaceuticals 51 KEMET Announces 51 Swine Flu Vaccine 51 Stocks Fluctuate 51 SulphCo Announces 51 Announce Licensing Agreement 51 Obtains FDA 51 Provides Guidance 51 Schizophrenia Treatment 51 Slightly Higher 51 REPEL CV 51 Temporary Shutdown 51 Licensing Deal 51 Equity Financing 51 Autologous Stem Cell Transplantation 51 Sign Pact 51 Higher Doses 51 Dose Ranging Study 51 Rocmec Closes 51 Multicenter Study 51 Osteoporosis Treatment 51 CLIA Waiver 51 Initiates Voluntary 51 Pharmacokinetic Study 51 Silicone Breast Implants 51 Reaches Pact 51 Sanvar R 51 Clinical Trial Application 51 Debt Concern 51 Premarket Approval 51 Receives Stockholder Approval 51 Resume Trading 51 PREVU x LT 51 Reduces Risk 51 Upcoming Milestones 51 Successfully Complete 51 Sevelamer 51 Stent Restenosis 51 Chugai Pharma 51 Successfully Tested 51 Cell Proliferation 51 Completes Patient Enrolment 51 Begins Clinical Trial 51 Acquire Majority Stake 51 SFDA approval 51 Therapeutic Competitors Companies 51 Exploitation Concession 51 IIa Clinical Trial 51 Executes Definitive Agreement 51 Launches Generic Version 51 Its Previously Announced 51 Univest Corporation Declares 51 Medoro Resources Announces 51 Pivotal Phase 51 Colorectal Cancer Patients 51 Sustained Efficacy 51 Million Financing 51 Influenza Vaccine 51 Resolves Dispute 51 Isavuconazole 51 Clears Path 51 Hypertensive Patients 51 Terminate Merger Agreement 51 Flamel Technologies Announces 51 Subsidiary Receives 51 Adjuvant Chemotherapy 51 Technological Advances 51 Provides Update 51 Stockholders Approve Merger 51 Receives SFDA Approval 51 ZTEST Announces 51 Shows Efficacy 51 Preclinical Data 51 Proposed Private Placement 51 Treated Patients 51 Trading Halted 51 Guidelines Issued 51 Kepivance 51 Announce Definitive Agreement 51 Awarded Qualifying Therapeutic 51 Diagnostic Tests 51 Results Confirm 51 Shareholder Meeting Date 51 Hepatocellular Carcinoma 51 Cholesterol Drugs 51 Vascular Disrupting Agent 51 Obtains Financing 51 Regains NASDAQ 51 Board Authorizes 51 Nears Completion 51 FDA Panel Recommends 51 Fast Tracked 51 Receives ISO #:# [002] 51 Stock Buyback Plan 51 successfully commercialize Iluvien 51 Drug Coated Stent 51 Completes Conversion 51 Paris IPN Euronext 51 Kirrin Resources Announces 51 CCHIT Certification 51 Antitumor Activity 51 Reconfirms 51 Issues Clarification 51 Versus Placebo 51 Enters Into LOI 51 Regulatory Filing 51 Second Tranche 51 DC Bead 51 Jumps Higher 51 Receives NASDAQ 51 Prophylactic Treatment 51 Biological License Application 51 Obtains Patent 51 Increases Non Brokered 51 Jointly Announce 51 Extends Collaboration 51 Plaque Psoriasis 51 Topical Treatment 51 Announces Effective Date 51 Loramyc ™ 51 Cash Tender Offers 51 Statistically Significant 51 Seeks Bids 51 Receives Regulatory Approvals 51 Multi Billion Dollar 51 BIOLASE Announces 51 Files Preliminary Prospectus 51 Collaborators Publish 51 Antiviral Activity 51 Cardiovascular Monitoring 51 Aloprim TM allopurinol sodium 51 NASDAQ UNIS 51 Withdraws Application 51 ARRY # 51 Vascular Grafts 51 Shows Promise 51 Shelf Registration 51 Successfully Treated 51 Myeloma Patients 51 Universal Flu Vaccine 51 TAXUS Element Paclitaxel Eluting 51 MBMI Closes 51 Demonstrates Sustained 51 Waiting Period 51 Completes Successful 51 Phase 2a Clinical Trial 51 Acquires Remaining 51 BioDelivery Sciences 51 Demonstrates Potent 51 Device Maker 51 Completes Asset 51 Aztreonam Lysine 51 Orapred ODT 51 Pushes Ahead 51 OvaRex R 51 Temporarily Suspends 51 EUR#.# Billion [002] 51 Acquire Assets 51 Therapeutic Vaccine 51 Gene Expression Analysis 51 Stocks Pare Gains 51 Biologic License Application 51 Doripenem 51 Prospective Randomized 51 FIRAZYR 51 Well Tolerated 51 Signs License Agreement 51 Vaccine Candidate 51 Strengthens Position 51 Submits Proposal 50 Engages CHF Investor Relations 50 OMAPRO ™ 50 HER2 Positive Breast Cancer 50 No Objection Letter 50 MAb therapy 50 Anti Tumor 50 Announces Intention 50 Capacity Expansion 50 ISO Certifications 50 Financing Commitment 50 Heart Stents 50 #.#/Share [002] 50 Randomized Double Blind 50 EUR#.# Billion [001] 50 Patent Validity 50 Orphan designation 50 Private Equity Financing 50 Expands Capabilities 50 Raptiva R 50 Enters Definitive Agreement 50 Settles Litigation 50 Delist From 50 Favorable Ruling 50 AVANIR Pharmaceuticals Announces 50 Issues Guidance 50 Permanent Injunction Against 50 Buyout Offer 50 Preliminary Injunction Against 50 Flu Vaccine 50 Reduces Mortality 50 NerPharMa 50 Obtains 50 Flu Virus 50 Arranges Non Brokered 50 Exclusive Licensing Agreement 50 HDAC Inhibitor 50 Genetic Tests 50 Initial Resource Estimate 50 Drilling Encounters 50 Febuxostat 50 Largest Ever 50 Molecular Diagnostic Test 50 Multicenter Phase 50 Holds Promise 50 Bradmer Pharmaceuticals 50 Response Biomedical Corporation 50 Regulators Warn 50 Emission Reductions 50 Loan Guarantees 50 Aloxi ® 50 Progresses 50 Announces Definitive Agreement 50 & Workover Fluids 50 JITC Certification 50 Receives Order 50 External Defibrillators 50 Somatuline R Autogel R 50 Demand Soars 50 PREOS R 50 Approvable Letter 50 Cyclacel Pharmaceuticals 50 Recombinant Human 50 Rotarix R 50 Drug Resistant 50 Emisphere Technologies Announces 50 Advanced Prostate Cancer 50 Laboratory Glassware 50 Therapeutic Competitors Report 50 Being Studied 50 InterOil Announces 50 Wizzard Software Announces 50 Flu Vaccinations 50 Commences Subsequent 50 Transaction Valued 50 Inovio Pharmaceuticals 50 Tissue Engineered 50 CryoSeal FS System 50 BioGlue R 50 Stocks Climb 50 Long Awaited 50 Pave Way 50 SABER ™ 50 Closes Flow Through 50 Contrast Agent 50 Remains Committed 50 Oracea ® 50 Announces Proposed 50 Dose Escalation 50 Receives Funding 50 Voluntary Withdrawal 50 Injection Site 50 highly purified pasteurized 50 Raises Bid 50 Dividend Declared 50 Increases Presence 50 Less Invasive 50 Adjuvant Therapy 50 Novel Antibiotic 50 Takeover Offer 50 Reclassifies 50 Artificial Cornea 50 Surgical Sealant 50 Investigational Agent 50 Issued Patent 50 Xcytrin R 50 Announce Early Termination 50 Announce Shareholder Approval 50 Output Declines 50 Signs Definitive Agreement 50 Ondansetron Injection 50 Sweetens Bid 50 Debt Refinancing 50 Announces Record Date 50 Unfractionated Heparin 50 PDL BioPharma Announces 50 Silicon Wafer 50 Flu Vaccines 50 Trade Pact 50 OTCBB RMCP 50 histamine dihydrochloride 50 Announces Completion 50 Dividend Payment 50 Antitumor 50 Reveals Significant 50 Protease Inhibitor 50 Sertraline Hydrochloride Tablets 50 NMT Medical Announces 50 RAPTIVA 50 Receives Favorable Ruling 50 Heartburn Drugs 50 Reloxin R 50 Slightly Lower 50 Common Share Offering 50 Acquires Remaining Interest 50 Cell Transplants 50 Patent Lawsuit 50 Radiofrequency Ablation 50 R bendamustine hydrochloride 50 Quadruples 50 Cancer Treatments 50 Has Commenced 50 Anthrax Vaccine 50 Announces Resumption 50 SBIR Grant 50 Fentanyl Patch 50 Patent Ruling 50 Stent Implantation 50 Rotavirus Vaccines 50 Secures Funding 50 Financing Transactions 50 Treatment Reduces 50 Gentamicin Surgical Implant 50 Contracts Totaling 50 Completes Divestiture 50 Controlling Stake 50 Commences Initial 50 Study Indicates 50 Dendritic Nanotechnologies Inc. 50 Headwaters Incorporated Announces 50 Finalizes Purchase 50 Announces Divestiture 50 Contracts Worth 50 Multicenter Randomized 50 InvestorSoup 50 Treatment Experienced 50 Pharmaceuticals Initiates 50 Underpins 50 Withdraws Offer 50 Entocort 50 Study Validates 50 Endeavor Drug Eluting 50 INFUSE R 50 Forges Ahead 50 Enters Into Agreements 50 Anti Nausea 50 Signs Binding Letter 50 Benazepril 50 Implant Sciences Receives 50 Accelerate Commercialization 50 EPC Contract 50 Alnylam Pharma 50 Geokinetics Announces 50 ISTODAX ® 50 ViRexx Announces 50 Acquire Controlling Stake 50 Majority Stake 50 ThermoDox R 50 Terminate Merger 50 Patent Infringement Case 50 Brilique 50 Excellon Announces 50 Vaccine Adjuvants 50 Mulls Sale 50 Awaits Approval 50 Treating Chronic 50 Continued Listing 50 Files Provisional